Aptus Pharma Ltd vs Mono Pharmacare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Aptus Pharma Ltd is ₹ 405 as of 30 Apr 15:30 . The P/E Ratio of Aptus Pharma Ltd is 0 as of March 2023 .The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023 . The Market Cap of Aptus Pharma Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Aptus Pharma Ltd is 0 % as of March 2023 .The Dividend Payout of Mono Pharmacare Ltd is 0 % as of March 2023.

About Aptus Pharma Ltd

Aptus Pharma Limited was originally incorporated as 'Aptus Pharma Private Limited', as a private limited company with the Registrar of Companies, Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010.
Subsequently, Company was converted into a public limited retaining the name as 'Aptus Pharma Limited' and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations.
While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model with 7 units. under various arrangements.
It provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products.

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

FAQs for the comparison of Aptus Pharma Ltd and Mono Pharmacare Ltd

Which company has a larger market capitalization, Aptus Pharma Ltd or Mono Pharmacare Ltd?

Market cap of Aptus Pharma Ltd is 277 Cr while Market cap of Mono Pharmacare Ltd is 23 Cr

What are the key factors driving the stock performance of Aptus Pharma Ltd and Mono Pharmacare Ltd?

The stock performance of Aptus Pharma Ltd and Mono Pharmacare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aptus Pharma Ltd and Mono Pharmacare Ltd?

As of May 4, 2026, the Aptus Pharma Ltd stock price is INR ₹405.0. On the other hand, Mono Pharmacare Ltd stock price is INR ₹13.25.

How do dividend payouts of Aptus Pharma Ltd and Mono Pharmacare Ltd compare?

To compare the dividend payouts of Aptus Pharma Ltd and Mono Pharmacare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.